Development of a bioluminescent homogenous nanobody-based immunoassay for the detection of prostate-specific antigen (PSA)
Enzyme and Microbial Technology · 2024
DOI: 10.1016/j.enzmictec.2024.110474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enzyme and Microbial Technology, 2024. Verfasst von Mahmoud Esraa Baghdadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Single-Domain Antibodies, Prostatic Neoplasms, Luminescent Measurements. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: University of Isfahan.
Abstract (Originalsprache)
Prostate cancer is the most prevalent cancer in men. At present, the diagnosis and screening of prostate cancer rely on the essential biomarker known as prostate-specific antigen (PSA). The main purpose of this study was to develop a novel immunoassay for the detection of PSA based on a tri-part split-nanoluciferase system and a nanobody targeting PSA. In our approach, two small components of the split-nanoluciferase, referred to as β9 and β10, were individually fused to two anti-PSA nanobodies, N7 and N23. When these proteins bind to PSA and in the presence of the third nanoluciferase component, called Δ11S, the split-nanoluciferase components are brought into close proximity, facilitating the reassembly of the active nanoluciferase and activation of luminescence. These proteins were expressed in a bacterial expression system, purified, and employed for the intended immunoassay. The developed immunoassay demonstrated the capability to sensitively detect PSA within a linear range from 1.0 to 20.0 ng/mL with LOD of 0.4 ng/mL, and the results obtained through this immunoassay agreed with those derived from the ELISA. Our study indicates that the homogeneous immunoassay developed with nanobodies exhibits remarkable specificity for PSA and can serve as a reliable, fast, and user-friendly test for detecting PSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran.
- Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran. Electronic address: r.emamzadeh@sci.ui.ac.ir.
- Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
- Department of Chemistry "Giacomo Ciamician", Alma Mater Studiorum-University of Bologna, Via Selmi 2, Bologna 40126, Italy.
Förderung
- University of Isfahan
Zitieren
APA
Baghdadi, M. E., Emamzadeh, R., Nazari, M., & Michelini, E. (2024). Development of a bioluminescent homogenous nanobody-based immunoassay for the detection of prostate-specific antigen (PSA). Enzyme and Microbial Technology. https://doi.org/10.1016/j.enzmictec.2024.110474
Vancouver
Baghdadi ME, Emamzadeh R, Nazari M, Michelini E. Development of a bioluminescent homogenous nanobody-based immunoassay for the detection of prostate-specific antigen (PSA). Enzyme and Microbial Technology. 2024. doi:10.1016/j.enzmictec.2024.110474
BibTeX
@article{Baghdadi2024,
author = {Baghdadi, Mahmoud Esraa and Emamzadeh, Rahman and Nazari, Mahboobeh and Michelini, Elisa},
title = {Development of a bioluminescent homogenous nanobody-based immunoassay for the detection of prostate-specific antigen (PSA)},
journal = {Enzyme and Microbial Technology},
year = {2024},
doi = {10.1016/j.enzmictec.2024.110474}
}
EUVIMED